Profile data is unavailable for this security.
About the company
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
- Revenue in USD (TTM)1.05bn
- Net income in USD-760.50m
- Incorporated2003
- Employees1.60k
- LocationEmergent BioSolutions Inc400 Professional Dr, Suite 400GAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 631-3200
- Fax+1 (240) 631-3203
- Websitehttps://emergentbiosolutions.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rezolute Inc | 0.00 | -56.83m | 114.77m | 51.00 | -- | 1.24 | -- | -- | -1.11 | -1.11 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -45.04 | -58.48 | -47.75 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Seres Therapeutics Inc | 126.33m | -113.72m | 114.77m | 233.00 | -- | -- | -- | 0.9085 | -0.897 | -0.897 | 0.9829 | -0.3322 | 0.3572 | -- | -- | 542,167.40 | -32.15 | -41.51 | -43.48 | -54.13 | -- | -- | -90.02 | -170.14 | 1.48 | -18.38 | 1.79 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Hongchang International Co Ltd | 2.68m | -378.79k | 115.49m | 8.00 | -- | 2.85 | -- | 43.16 | -0.0009 | -0.0009 | 0.0071 | 0.078 | 0.1065 | -- | 2.78 | -- | -1.51 | -7.98 | -1.60 | -10.94 | 2.59 | 11.47 | -14.16 | -64.88 | 3.74 | -- | 0.1417 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -22.26m | 117.10m | 13.00 | -- | 9.41 | -- | -- | -1.42 | -1.42 | 0.00 | 0.7005 | 0.00 | -- | -- | 0.00 | -112.45 | -- | -168.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Coya Therapeutics Inc | 6.00m | -7.99m | 117.11m | 8.00 | -- | 3.24 | -- | 19.51 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -42.94m | 117.37m | 25.00 | -- | 4.05 | -- | -- | -1.39 | -1.39 | 0.00 | 0.7896 | 0.00 | -- | -- | 0.00 | -62.97 | -51.63 | -76.04 | -59.00 | -- | -- | -- | -- | -- | -33.04 | 0.4772 | -- | -- | -- | -5.11 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -98.79m | 117.98m | 20.00 | -- | 1.38 | -- | -- | -3.28 | -3.28 | 0.00 | 2.84 | 0.00 | -- | -- | 0.00 | -78.89 | -- | -87.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -36.90m | 118.27m | 35.00 | -- | 3.08 | -- | 11,826.65 | -0.5841 | -0.5841 | 0.0002 | 0.5966 | 0.0002 | -- | 0.0625 | 285.71 | -75.98 | -43.60 | -90.65 | -47.82 | -- | -- | -368,994.20 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Emergent Biosolutions Inc | 1.05bn | -760.50m | 119.97m | 1.60k | -- | 0.1841 | -- | 0.1143 | -14.75 | -14.75 | 20.43 | 12.44 | 0.4206 | 2.08 | 5.99 | 655,812.50 | -30.48 | -2.94 | -48.92 | -3.66 | 32.77 | 53.24 | -72.48 | -5.95 | 0.5383 | -1.96 | 0.5699 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.33m | 122.07m | 22.00 | -- | 1.44 | -- | -- | -0.255 | -0.255 | 0.00 | 0.533 | 0.00 | -- | -- | 0.00 | -36.52 | -30.26 | -38.61 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -81.41m | 122.44m | 54.00 | -- | 1.36 | -- | -- | -5.11 | -5.11 | 0.00 | 2.35 | 0.00 | -- | -- | 0.00 | -113.72 | -80.06 | -136.52 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Biostem Technologies Inc | -100.00bn | -100.00bn | 124.46m | 67.00 | -- | -- | -- | -- | -- | -- | -- | -0.2692 | -- | -- | -- | -- | -- | -107.46 | -- | -- | -- | 59.17 | -- | -120.14 | 0.4177 | -- | 2.41 | -- | 72.14 | 47.77 | 42.48 | -- | -- | -- |
| Inotiv Inc | 585.17m | -33.21m | 125.08m | 1.96k | -- | 0.4922 | 5.71 | 0.2138 | -1.29 | -1.29 | 22.73 | 9.85 | 0.6858 | 6.46 | 7.12 | 299,320.70 | -3.96 | -23.84 | -4.62 | -29.26 | 30.29 | 29.31 | -5.78 | -33.24 | 1.28 | 0.1431 | 0.5988 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
Data as of Apr 25 2024. Currency figures normalised to Emergent BioSolutions Inc's reporting currency: US Dollar USD
40.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.63m | 10.79% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.93m | 5.62% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 2.87m | 5.51% |
| Millennium Management LLCas of 31 Dec 2023 | 2.10m | 4.01% |
| Hotchkis & Wiley Capital Management LLCas of 31 Dec 2023 | 1.65m | 3.16% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 1.57m | 3.00% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 1.19m | 2.27% |
| BlackRock Financial Management, Inc.as of 31 Dec 2023 | 1.13m | 2.16% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.10m | 2.10% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.09m | 2.09% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
